drugset / Trial / NCT03748628

Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects

NCT03748628

Phase 1 Completed 8 enrolled Enanta Pharmaceuticals, Inc
NaSingle-groupOpen-labelBasic science

Summary

A Phase 1, Open-label Study of the absorption, metabolism, and excretion of a single oral dose of \[14C\]EDP-305 in healthy male subjects.

Timeline

Start
2018-10-05
Primary completion
2018-10-13
Completion
2018-10-13

Drugs

EvaluationDrugModalityDoseRoute
Subject EDP-305 Unknown Oral